Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atr... | NCT00911508

ID	Type	Description	Link
U01HL089709	U.S. NIH Grant/Contract		View source

Status Module

Name	Class
National Heart, Lung, and Blood Institute (NHLBI)	NIH
Abbott Medical Devices	INDUSTRY
Biosense Webster, Inc.	INDUSTRY

Description Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Left Atrial Ablation	Active Comparator	Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided approach, or wide area circumferential ablation.	Device: Left atrial ablation
Rate or Rhythm Control Therapy	Active Comparator	Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating physicians will be encouraged to follow the American College of Cardiology / American Heart Association / European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation. The specific choice of rate control versus rhythm control drug therapy and the specific drugs to be used will ultimately be left to the discretion of the treating physician.	Drug: Rate or Rhythm Control Therapy

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Left atrial ablation	Device	St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System Bard: Stinger Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of Participants With Composite of Total Mortality, Disabling Stroke, Serious Bleeding, or Cardiac Arrest in Patients Warranting Therapy for AF.	All events for each component of the primary endpoint were reviewed and adjudicated in a blinded fashion by an independent clinical events committee using prospectively determined event definitions. Death was defined as all-cause mortality, disabling stroke (including intracranial bleeding) as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2, and serious bleeding as bleeding accompanied by hemodynamic compromise that required surgical intervention or a transfusion of ≥3 units of blood.	From date of enrollment until time-to-first event over a median follow-up of 48.5 months.

Secondary Outcomes

Measure	Description	Time Frame
Number of Participants With All-cause Mortality	All deaths were reviewed and adjudicated by the Clinical Events Committee	From date of enrollment until date of death over a median follow-up of 48.5 months.
Number of Participants With Mortality or Cardiovascular (CV) Hospitalization

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Over the preceding 6 months have:
1. ≥2 paroxysmal (electrocardiographic documentation of at least 1) atrial fibrillation (AF) episodes lasting ≥1 hour in duration: (that terminate spontaneously within 7 days or cardioversion is performed within 48h of AF onset): or
2. electrocardiographic documentation of 1 persistent AF episode: (sustained for ≥7 days or cardioversion is performed more than 48h after AF onset): or
3. electrocardiographic documentation of 1 longstanding persistent AF episode: (continuous AF of duration >1 year).
Warrant active therapy (within the past 3 months) beyond simple ongoing observation
Be eligible for catheter ablation and ≥2 sequential rhythm control and/or ≥2 rate control drugs.
Be ≥65 yrs of age, or <65 yrs with one or more of the following risk factors for stroke: Hypertension (treated and/or defined as a blood pressure >140/90 mmHg) [90], Diabetes (treated and/or defined as a fasting glucose ≥126 mg/dl) [91], Congestive heart failure (including systolic or diastolic heart failure), Prior stroke, transient ischemic attack or systemic emboli, Atherosclerotic vascular disease (previous myocardial infarction (MI), peripheral arterial disease or aortic plaque), left atrial (LA) size >5.0 cm (or volume index ≥40 cc/m2), or ejection fraction (EF) ≤35.
Have the capacity to understand and sign an informed consent form.
Be ≥18 years of age.
- NOTE- Subjects <65 yrs of age whose only risk factor is hypertension must have a second risk factor or left ventricular (LV) hypertrophy to qualify.Patients receiving new drug therapy initiated within the previous 3 months may continue that therapy if randomized to the drug therapy arm. Patients may have documented atrial flutter in addition to atrial fibrillation and remain eligible for enrollment.

Exclusion Criteria:

Lone AF in the absence of risk factors for stroke in patients <65 years of age
Patients who in the opinion of the managing clinician should not yet receive any therapy for AF
Patients who have failed >2 membrane active anti-arrhythmic drugs at a therapeutic dose due to inefficacy or side effects (Table 5.2.2)
An efficacy failure of full dose amiodarone treatment >8 weeks duration at any time
Reversible causes of AF including thyroid disorders, acute alcohol intoxication, recent major surgical procedures, or trauma
Recent cardiac events including MI, percutaneous intervention (PCI), or valve or bypass surgery in the preceding 3 months
Hypertrophic obstructive cardiomyopathy (outflow track)
Class IV angina or Class IV congestive heart failure (CHF) (including past or planned heart transplantation)
Other arrhythmias mandating anti-arrhythmic drug therapy (i.e. ventricular tachycardia (VT), ventricular fibrillation (VF))
Heritable arrhythmias or increased risk for torsade de pointes with class I or III drugs
Prior LA catheter ablation with the intention of treating AF
Prior surgical interventions for AF such as the MAZE procedure
Prior AV nodal ablation
Patients with other arrhythmias requiring ablative therapy
Contraindication to appropriate anti-coagulation therapy
Renal failure requiring dialysis
Medical conditions limiting expected survival to <1 year
Women of childbearing potential (unless post-menopausal or surgically sterile)
Participation in any other clinical mortality trial (Participation in other non-mortality trials should be reviewed with the clinical trial management center)
Unable to give informed consent
- NOTE- Prior ablation of the cavo-tricuspid isthmus alone is not an exclusion if the patient develops subsequent recurrent AF. Planned atrial flutter ablation in combination with the left atrial ablation is not an exclusion.

Name	Affiliation	Role
Douglas L. Packer, M.D.	Mayo Clinic	Principal Investigator
Kerry L. Lee, Ph.D.	Duke Clinical Research Institute	Principal Investigator
Daniel B. Mark, M.D., MPH	Duke Clinical Research Institute	Principal Investigator
Rich A. Robb, Ph.D. Phy	Mayo Clinic	Principal Investigator
Yves D. Rosenberg, M.D., MPH	National Heart, Lung, and Blood Institute (NHLBI)	Study Chair

Facility	Status	City	State	ZIP	Country	Contacts
Arkansas Cardiology, PA		Little Rock	Arkansas	72205	United States
Good Samaritan Hospital

PubMed Identifier	Type	Citation	Retractions
42419471	Derived	Li W, Sudell M, Chen Y, Zhao M, Kelson M, Gupta D, Zheng Y, Packer DL, Meng Y, Lip GYH. Latent Class Analysis to Identify Phenotype-Specific Treatment Effects of Catheter Ablation Versus Drug Therapy in Patients with Atrial Fibrillation: A Secondary Analysis of the CABANA Trial. Heart Rhythm. 2026 Jul 8:S1547-5271(26)02540-3. doi: 10.1016/j.hrthm.2026.07.008. Online ahead of print.
41526927	Derived	Zhao M, Chen Y, Li M, Jiang C, Wang Z, Liu H, He L, Sang C, Du X, Dong J, Packer DL, Ma C, Lip GYH. Impact of diagnosis to ablation time on clinical outcomes in patients with atrial fibrillation: post hoc analysis of the CABANA trial. BMC Med. 2026 Jan 12;24(1):81. doi: 10.1186/s12916-026-04615-3.

Label	URL
Mayo Clinic Clinical Trials	View source

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
FG001

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Nov 22, 2013	Dec 20, 2018

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Customized

Median

Inter-Quartile Range

years

Title

Denominators

Categories

Title	Measurements
	OG00089 OG001101

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001						Cox Proportional Hazard	0.86			2-Sided	95	0.65	1.15					Superiority

Secondary

Number of Participants With All-cause Mortality

All deaths were reviewed and adjudicated by the Clinical Events Committee

Posted

Count of Participants

Participants

From date of enrollment until date of death over a median follow-up of 48.5 months.

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Units	Counts
Participants	OG000

Secondary

Number of Participants With Mortality or Cardiovascular (CV) Hospitalization

Hospitalization was characterized by the site principal investigator (PI) and reported as part of the hospitalization case report form.

Posted

Count of Participants

Participants

From date of enrollment until time-to-first event of death or CV hospitalization over a median follow-up of 48.5 months.

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Units	Counts
Participants	OG000

Secondary

Number of Participants With Mortality, Disabling Stroke, or CV Hospitalization (for Heart Failure or Acute Ischemic Events)

Disabling stroke (including intracranial bleeding) was defined as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2 and the reason for hospitalization was characterized by the site PI and reported as part of the hospitalization case report form.

Posted

Count of Participants

Participants

From date of enrollment until time-to-first event of death, stroke, or CV hospitalization (for heart failure or acute ischemic event) over a median follow-up of 48.5 months.

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Units	Counts

Secondary

Number of Participants With Cardiovascular Death

Cardiovascular death as determined by the Clinical Events Committee based on the available data provided by the Principal Investigator

Posted

Count of Participants

Participants

From date of enrollment until date of a cardiovascular death over a median follow-up of 48.5 months.

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Units	Counts
Participants	OG000

Secondary

Number of Participants With Cardiovascular Death or Disabling Stroke

Disabling stroke (including intracranial bleeding) was defined as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2.

Posted

Count of Participants

Participants

From date of enrollment until time-to-first event of a cardiovascular death or disabling stroke over a median follow-up of 48.5 months.

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Units	Counts
Participants	OG000

Secondary

Number of Participants With an Arrhythmic Death or Cardiac Arrest

All deaths and cardiac arrest events were adjudicated by the Clinical Events Committee

Posted

Count of Participants

Participants

From date of enrollment until time-to-first event for an arrhythmic death or cardiac arrest over a median follow-up of 48.5 months.

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Units	Counts
Participants	OG000

Secondary

Number of Participants With Heart Failure Death

All deaths were categorized and adjudicated by the Clinical Events Committee

Posted

Count of Participants

Participants

From date of enrollment until date of heart failure death over a median follow-up of 48.5 months.

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Units	Counts
Participants	OG000

Secondary

Number of Participants Free From Recurrent Atrial Fibrillation (AF) Following the 90 Day Blanking Period

Data from patients using the study provided ECG event recording system were analyzed. A 30-second episode of AF in either group, confirmed through blinded review by an ECG Core Lab Committee was used for defining the endpoint of recurrent AF.

Subjects were analyzed in the post-blanking period if randomized treatment occurred and the subject did not die, withdraw, or get lost to follow-up before the end of the 90 day blanking period.

Posted

Count of Participants

Participants

From date of therapy initiation until date of first AF recurrence following a 90 day wait (blanking) period over a median follow-up of 48.5 months.

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Secondary

Number of Participants With Cardiovascular Hospitalization

The reason for hospitalization was characterized by the site PI and reported as part of the hospitalization case report form.

Posted

Count of Participants

Participants

From date of enrollment until date of cardiovascular hospitalization over a median follow-up of 48.5 months.

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Units	Counts
Participants	OG000

Secondary

Changes in Quality of Life Measures - AFEQT

Atrial Fibrillation Effect on Quality of Life (AFEQT) Overall Score (Scale: 0 = complete disability, 100 = no disability). The AFEQT is a 21-item AF-specific, health-related QOL questionnaire designed to assess the effect of atrial fibrillation on patient quality of life. The AFEQT has an Overall Score (calculated from 18 of the questions) and subscale scores in three domains: symptoms, daily activities, and treatment concern. Overall and subscale scores range from 0 (corresponds to complete disability) to 100 (no AF-related disability).

Only patients with questionnaire data were analyzed.

Posted

Mean

Standard Deviation

units on a scale

Baseline ,12 month, 5 years

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Secondary

Changes in Quality of Life Measures - MAFSI Frequency Score

The Mayo AF-Specific Symptom Inventory (MAFSI) is a questionnaire comprised of a 10-item AF symptom checklist that asked about both the frequency and severity of each symptom. MAFSI frequency of symptoms over the past month was recorded as 0 (never), 1 (rarely), 2 (sometimes), 3 (often), and 4 (always) for each of the 10 items listed in the questionnaire. The 10 item responses were summed for a total Frequency Score that ranged from 0 (no AF symptoms) to 40 (worst score).

Only patients with questionnaire data were analyzed.

Posted

Mean

Standard Deviation

units on a scale

Baseline, 12 Month, 5 Year

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Secondary

Changes in Quality of Life Measures - MAFSI Severity Score

The Mayo AF-Specific Symptom Inventory (MAFSI) is a questionnaire comprised of a 10-item AF symptom checklist that asked about both the frequency and severity of each symptom. MAFSI severity scores over the past month were recorded as 1 (mild), 2 (moderate), and 3 (extreme) for each of the 10 items listed in the questionnaire. The 10 items items were then summed for the total Severity Score that ranged from 0 (no AF symptoms) to 30 (most severe AF symptoms).

Only patients with questionnaire data were analyzed.

Posted

Mean

Standard Deviation

units on a scale

Baseline, 12 Month, 5 Year

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Secondary

Number of Participants With Adverse Events/Complications

Comparing individual non-endpoint adverse events between ablative and drug therapy is difficult due to the substantial difference in the types of adverse events expected.

Ablation-related events were counted among all patients that were randomized to and received an ablation.

Drug-related events were counted among all patients that were randomized to and received drug therapy.

Ablation-related events were counted among all patients that were randomized to and received an ablation.

Drug-related events were counted among all patients that were randomized to and received drug therapy.

Posted

Count of Participants

Participants

From treatment start date to date of event over a median follow-up of 48.5 months.

ID	Title	Description
OG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
OG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.

Serious Adverse Events

Term	Organ System	Assessment Type	Statistical Information
ANAEMIA	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0015 events5 affected1,096 at risk
ANAEMIA OF MALIGNANT DISEASE	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
AUTOIMMUNE HAEMOLYTIC ANAEMIA	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
FEBRILE NEUTROPENIA	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
HAEMORRHAGIC DISORDER	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
IMMUNE THROMBOCYTOPENIC PURPURA	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
IRON DEFICIENCY ANAEMIA	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0013 events3 affected1,096 at risk
THROMBOCYTOPENIA	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
ACUTE CORONARY SYNDROME	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
ACUTE MYOCARDIAL INFARCTION	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
ANGINA PECTORIS	Cardiac disorders	Systematic Assessment	EG0007 events7 affected1,108 at risk EG0015 events5 affected1,096 at risk
ANGINA UNSTABLE	Cardiac disorders	Systematic Assessment	EG0004 events4 affected1,108 at risk EG0015 events4 affected1,096 at risk
AORTIC VALVE INCOMPETENCE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
AORTIC VALVE STENOSIS	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
ARRHYTHMIA	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ARTERIOSCLEROSIS CORONARY ARTERY	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
ATRIAL FLUTTER	Cardiac disorders	Systematic Assessment	EG0007 events7 affected1,108 at risk EG0016 events5 affected1,096 at risk
ATRIAL SEPTAL DEFECT ACQUIRED	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ATRIAL TACHYCARDIA	Cardiac disorders	Systematic Assessment	EG0008 events6 affected1,108 at risk EG0012 events1 affected1,096 at risk
ATRIAL THROMBOSIS	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
ATRIOVENTRICULAR BLOCK	Cardiac disorders	Systematic Assessment	EG0007 events7 affected1,108 at risk EG0013 events3 affected1,096 at risk
ATRIOVENTRICULAR BLOCK COMPLETE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ATRIOVENTRICULAR BLOCK SECOND DEGREE	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
BRADYCARDIA	Cardiac disorders	Systematic Assessment	EG00018 events18 affected1,108 at risk EG00128 events25 affected1,096 at risk
BUNDLE BRANCH BLOCK LEFT	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CARDIAC ARREST	Cardiac disorders	Systematic Assessment	EG00010 events10 affected1,108 at risk EG00110 events9 affected1,096 at risk
CARDIAC FAILURE	Cardiac disorders	Systematic Assessment	EG00090 events60 affected1,108 at risk EG00177 events47 affected1,096 at risk
CARDIAC FAILURE ACUTE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CARDIAC FAILURE CHRONIC	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CARDIAC FAILURE CONGESTIVE	Cardiac disorders	Systematic Assessment	EG0004 events4 affected1,108 at risk EG0013 events3 affected1,096 at risk
CARDIAC PERFORATION	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
CARDIAC TAMPONADE	Cardiac disorders	Systematic Assessment	EG00010 events10 affected1,108 at risk EG0011 events1 affected1,096 at risk
CARDIAC VALVE DISEASE	Cardiac disorders	Systematic Assessment	EG0004 events4 affected1,108 at risk EG0015 events5 affected1,096 at risk
CARDIAC VENTRICULAR THROMBOSIS	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CARDIOGENIC SHOCK	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CARDIOMYOPATHY	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CORONARY ARTERY DISEASE	Cardiac disorders	Systematic Assessment	EG0009 events9 affected1,108 at risk EG0013 events3 affected1,096 at risk
CORONARY ARTERY EMBOLISM	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CORONARY ARTERY OCCLUSION	Cardiac disorders	Systematic Assessment	EG0005 events4 affected1,108 at risk EG0017 events6 affected1,096 at risk
CORONARY ARTERY STENOSIS	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0011 events1 affected1,096 at risk
INTRACARDIAC THROMBUS	Cardiac disorders	Systematic Assessment	EG0005 events5 affected1,108 at risk EG0010 events0 affected1,096 at risk
LEFT VENTRICULAR DYSFUNCTION	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
MITRAL VALVE INCOMPETENCE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
MITRAL VALVE STENOSIS	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
MYOCARDIAL INFARCTION	Cardiac disorders	Systematic Assessment	EG0008 events7 affected1,108 at risk EG00120 events18 affected1,096 at risk
MYOCARDIAL ISCHAEMIA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
MYOCARDITIS	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
PALPITATIONS	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
PERICARDIAL EFFUSION	Cardiac disorders	Systematic Assessment	EG00024 events22 affected1,108 at risk EG0013 events3 affected1,096 at risk
PERICARDITIS	Cardiac disorders	Systematic Assessment	EG0008 events8 affected1,108 at risk EG0012 events2 affected1,096 at risk
PERICARDITIS CONSTRICTIVE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
SINOATRIAL BLOCK	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0014 events4 affected1,096 at risk
SINUS ARREST	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
SINUS BRADYCARDIA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
SINUS NODE DYSFUNCTION	Cardiac disorders	Systematic Assessment	EG00010 events10 affected1,108 at risk EG00113 events13 affected1,096 at risk
TACHYARRHYTHMIA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
TACHYCARDIA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
TACHYCARDIA INDUCED CARDIOMYOPATHY	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
TRICUSPID VALVE DISEASE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
VENTRICULAR ARRHYTHMIA	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
VENTRICULAR EXTRASYSTOLES	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0012 events2 affected1,096 at risk
VENTRICULAR FIBRILLATION	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0013 events3 affected1,096 at risk
VENTRICULAR TACHYCARDIA	Cardiac disorders	Systematic Assessment	EG00013 events11 affected1,108 at risk EG00111 events9 affected1,096 at risk
ATRIAL SEPTAL DEFECT	Congenital, familial and genetic disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HYDROCELE	Congenital, familial and genetic disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HYPERTROPHIC CARDIOMYOPATHY	Congenital, familial and genetic disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
MUSCULAR DYSTROPHY	Congenital, familial and genetic disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
PATENT DUCTUS ARTERIOSUS	Congenital, familial and genetic disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
DEAFNESS	Ear and labyrinth disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DEAFNESS UNILATERAL	Ear and labyrinth disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
SUDDEN HEARING LOSS	Ear and labyrinth disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
TYMPANIC MEMBRANE PERFORATION	Ear and labyrinth disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
VERTIGO POSITIONAL	Ear and labyrinth disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
VESTIBULAR DISORDER	Ear and labyrinth disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HYPERTHYROIDISM	Endocrine disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0013 events3 affected1,096 at risk
HYPOTHYROIDISM	Endocrine disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0013 events3 affected1,096 at risk
CATARACT	Eye disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
CATARACT NUCLEAR	Eye disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
DIPLOPIA	Eye disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
MACULAR FIBROSIS	Eye disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
OPTIC NERVE DISORDER	Eye disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
RETINAL ARTERY OCCLUSION	Eye disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
RETINAL DETACHMENT	Eye disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
VITREOUS HAEMORRHAGE	Eye disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ABDOMINAL HERNIA	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ABDOMINAL HERNIA OBSTRUCTIVE	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ABDOMINAL PAIN	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events1 affected1,096 at risk
ABDOMINAL PAIN LOWER	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ABDOMINAL WALL HAEMATOMA	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
ALCOHOLIC PANCREATITIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
COLITIS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
COLITIS ISCHAEMIC	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CONSTIPATION	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
CROHN'S DISEASE	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DIARRHOEA	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0012 events2 affected1,096 at risk
DUODENAL ULCER	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DUODENAL ULCER PERFORATION	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
EROSIVE OESOPHAGITIS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
FAECAL INCONTINENCE	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
GASTRIC DISORDER	Gastrointestinal disorders	Systematic Assessment	EG0005 events5 affected1,108 at risk EG0014 events4 affected1,096 at risk
GASTRIC HAEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
GASTRITIS	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0011 events1 affected1,096 at risk
GASTROINTESTINAL HAEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG00010 events10 affected1,108 at risk EG00111 events10 affected1,096 at risk
GASTROOESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0014 events4 affected1,096 at risk
HAEMATEMESIS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
HAEMORRHOIDAL HAEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
HAEMORRHOIDS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HIATUS HERNIA	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ILEUS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
INGUINAL HERNIA	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0013 events3 affected1,096 at risk
INGUINAL HERNIA STRANGULATED	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
INTESTINAL HAEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events1 affected1,096 at risk
INTESTINAL ISCHAEMIA	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
INTESTINAL MASS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
INTESTINAL OBSTRUCTION	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events1 affected1,096 at risk
LOWER GASTROINTESTINAL HAEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0015 events4 affected1,096 at risk
MALLORY-WEISS SYNDROME	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
MELAENA	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
NAUSEA	Gastrointestinal disorders	Systematic Assessment	EG0002 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
OESOPHAGEAL DISORDER	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
OESOPHAGITIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
PANCREATIC PSEUDOCYST	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
PANCREATITIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
PANCREATITIS ACUTE	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0010 events0 affected1,096 at risk
PANCREATITIS RELAPSING	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
PERITONEAL HAEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
PNEUMOPERITONEUM	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
RECTAL HAEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0012 events2 affected1,096 at risk
RECTAL PROLAPSE	Gastrointestinal disorders	Systematic Assessment	EG0002 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
RECTAL ULCER HAEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
SMALL INTESTINAL OBSTRUCTION	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0013 events3 affected1,096 at risk
SMALL INTESTINAL ULCER HAEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
SUBILEUS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
TONGUE GEOGRAPHIC	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
UPPER GASTROINTESTINAL HAEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0014 events4 affected1,096 at risk
VOMITING	Gastrointestinal disorders	Systematic Assessment	EG0006 events6 affected1,108 at risk EG0012 events2 affected1,096 at risk
ADVERSE DRUG REACTION	General disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CARDIAC DEATH	General disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CHEST DISCOMFORT	General disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CHEST PAIN	General disorders	Systematic Assessment	EG0004 events4 affected1,108 at risk EG0012 events2 affected1,096 at risk
DEATH	General disorders	Systematic Assessment	EG00014 events14 affected1,108 at risk EG00111 events11 affected1,096 at risk
DEVICE MALFUNCTION	General disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
FATIGUE	General disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
GAIT DISTURBANCE	General disorders	Systematic Assessment	EG0003 events2 affected1,108 at risk EG0012 events2 affected1,096 at risk
HERNIA	General disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
IMPAIRED HEALING	General disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
MEDICAL DEVICE COMPLICATION	General disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
NON-CARDIAC CHEST PAIN	General disorders	Systematic Assessment	EG0005 events4 affected1,108 at risk EG0014 events4 affected1,096 at risk
PAIN	General disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0014 events4 affected1,096 at risk
PYREXIA	General disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
STENT-GRAFT ENDOLEAK	General disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
ACUTE HEPATIC FAILURE	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
BILE DUCT STONE	Hepatobiliary disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
CHOLECYSTITIS	Hepatobiliary disorders	Systematic Assessment	EG0005 events5 affected1,108 at risk EG0011 events1 affected1,096 at risk
CHOLECYSTITIS ACUTE	Hepatobiliary disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
CHOLELITHIASIS	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CHRONIC HEPATITIS	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
HEPATIC CIRRHOSIS	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
HEPATIC FAILURE	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
NON-ALCOHOLIC STEATOHEPATITIS	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ANAPHYLACTIC SHOCK	Immune system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HYPERSENSITIVITY	Immune system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0013 events3 affected1,096 at risk
ABSCESS LIMB	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ABSCESS SOFT TISSUE	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ANAL ABSCESS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ANORECTAL INFECTION	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
APPENDICITIS	Infections and infestations	Systematic Assessment	EG0002 events1 affected1,108 at risk EG0013 events3 affected1,096 at risk
BACTERAEMIA	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
BRONCHITIS	Infections and infestations	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
CELLULITIS	Infections and infestations	Systematic Assessment	EG0007 events7 affected1,108 at risk EG0013 events3 affected1,096 at risk
CHOLECYSTITIS INFECTIVE	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
DEVICE RELATED INFECTION	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events1 affected1,096 at risk
DIABETIC FOOT INFECTION	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DIABETIC GANGRENE	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DIVERTICULITIS	Infections and infestations	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0017 events6 affected1,096 at risk
ERYSIPELAS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
GASTROENTERITIS	Infections and infestations	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0012 events2 affected1,096 at risk
GASTROENTERITIS CLOSTRIDIAL	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
GASTROENTERITIS VIRAL	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
HAEMOPHILUS INFECTION	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
INFECTION	Infections and infestations	Systematic Assessment	EG00011 events11 affected1,108 at risk EG00111 events10 affected1,096 at risk
INFLUENZA	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
LUNG ABSCESS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
LYME DISEASE	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
MEDICAL DEVICE SITE INFECTION	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
NASOPHARYNGITIS	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
OSTEOMYELITIS	Infections and infestations	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
PNEUMONIA	Infections and infestations	Systematic Assessment	EG00037 events32 affected1,108 at risk EG00134 events29 affected1,096 at risk
PNEUMONIA BACTERIAL	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
POST PROCEDURAL CELLULITIS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
POSTOPERATIVE WOUND INFECTION	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
PULMONARY TUBERCULOSIS	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
PYELONEPHRITIS	Infections and infestations	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0011 events1 affected1,096 at risk
SALMONELLA BACTERAEMIA	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
SALMONELLOSIS	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
SEPSIS	Infections and infestations	Systematic Assessment	EG00012 events11 affected1,108 at risk EG00112 events11 affected1,096 at risk
SEPTIC SHOCK	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
STAPHYLOCOCCAL BACTERAEMIA	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
STAPHYLOCOCCAL INFECTION	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
STREPTOCOCCAL BACTERAEMIA	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
STREPTOCOCCAL SEPSIS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
UPPER RESPIRATORY TRACT INFECTION	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
URINARY TRACT INFECTION	Infections and infestations	Systematic Assessment	EG00012 events12 affected1,108 at risk EG00110 events10 affected1,096 at risk
UROSEPSIS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
VULVAL ABSCESS	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ACCIDENTAL OVERDOSE	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ANASTOMOTIC LEAK	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ANKLE FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
BRAIN CONTUSION	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
BURN OESOPHAGEAL	Injury, poisoning and procedural complications	Systematic Assessment	EG0005 events5 affected1,108 at risk EG0010 events0 affected1,096 at risk
CONCUSSION	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CONTRAST MEDIA REACTION	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CONTUSION	Injury, poisoning and procedural complications	Systematic Assessment	EG0002 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CRANIOCEREBRAL INJURY	Injury, poisoning and procedural complications	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
FALL	Injury, poisoning and procedural complications	Systematic Assessment	EG0009 events7 affected1,108 at risk EG0011 events1 affected1,096 at risk
FEMORAL NECK FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
FEMUR FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0013 events2 affected1,096 at risk
FIBULA FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
FOOT FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
GUN SHOT WOUND	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HAND FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
HEAD INJURY	Injury, poisoning and procedural complications	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
HEAT EXHAUSTION	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HIP FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0011 events1 affected1,096 at risk
HUMERUS FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
INCISIONAL HERNIA	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0013 events3 affected1,096 at risk
INJURY	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
LACERATION	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
MENTAL STATUS CHANGES POSTOPERATIVE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
NERVE INJURY	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
PATELLA FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
PELVIC FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
POST CONCUSSION SYNDROME	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
POST PROCEDURAL COMPLICATION	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
POST PROCEDURAL HAEMORRHAGE	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
POSTOPERATIVE ILEUS	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
RADIATION SKIN INJURY	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
RADIUS FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
RIB FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0004 events4 affected1,108 at risk EG0010 events0 affected1,096 at risk
ROAD TRAFFIC ACCIDENT	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
SPINAL COMPRESSION FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
SPLENIC RUPTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
SUBDURAL HAEMATOMA	Injury, poisoning and procedural complications	Systematic Assessment	EG00011 events11 affected1,108 at risk EG0013 events2 affected1,096 at risk
TENDON RUPTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
THORACIC VERTEBRAL FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
TIBIA FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
TOXICITY TO VARIOUS AGENTS	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
TRAUMATIC HAEMATOMA	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
VASCULAR PSEUDOANEURYSM	Injury, poisoning and procedural complications	Systematic Assessment	EG00011 events11 affected1,108 at risk EG0013 events3 affected1,096 at risk
WOUND	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
WRIST FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ANTICOAGULATION DRUG LEVEL ABOVE THERAPEUTIC	Investigations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
BLOOD BICARBONATE DECREASED	Investigations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
BODY TEMPERATURE INCREASED	Investigations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0013 events3 affected1,096 at risk
ELECTROCARDIOGRAM QT PROLONGED	Investigations	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
INTERNATIONAL NORMALISED RATIO ABNORMAL	Investigations	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
LIVER FUNCTION TEST ABNORMAL	Investigations	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
DEHYDRATION	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
DIABETES MELLITUS	Metabolism and nutrition disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
DIABETES MELLITUS INADEQUATE CONTROL	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
DIABETIC KETOACIDOSIS	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
FAILURE TO THRIVE	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
FLUID OVERLOAD	Metabolism and nutrition disorders	Systematic Assessment	EG00010 events10 affected1,108 at risk EG0015 events5 affected1,096 at risk
GOUT	Metabolism and nutrition disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0011 events1 affected1,096 at risk
HYPERGLYCAEMIA	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
HYPOGLYCAEMIA	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0013 events2 affected1,096 at risk
HYPOKALAEMIA	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HYPONATRAEMIA	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
MALNUTRITION	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
METABOLIC ACIDOSIS	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
OBESITY	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
TYPE 2 DIABETES MELLITUS	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ARTHRITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0004 events3 affected1,108 at risk EG0012 events2 affected1,096 at risk
BACK PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
BONE DISORDER	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
BURSITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CHONDROCALCINOSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CHONDROCALCINOSIS PYROPHOSPHATE	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CHONDROPATHY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
COSTOCHONDRITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
GOUTY ARTHRITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
GOUTY TOPHUS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HAEMARTHROSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events1 affected1,096 at risk
INTERVERTEBRAL DISC PROTRUSION	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
MUSCLE DISORDER	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
MUSCULAR WEAKNESS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
MUSCULOSKELETAL CHEST PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
MUSCULOSKELETAL PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
NECK PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00021 events18 affected1,108 at risk EG00128 events24 affected1,096 at risk
OSTEOCHONDROSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
OSTEOPOROTIC FRACTURE	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
PAIN IN EXTREMITY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
RHEUMATOID ARTHRITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
ROTATOR CUFF SYNDROME	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0012 events2 affected1,096 at risk
SCLERODERMA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
SCOLIOSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
SPINAL COLUMN STENOSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events1 affected1,096 at risk
SPONDYLOLISTHESIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
ACUTE MYELOID LEUKAEMIA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ANOGENITAL WARTS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
APPENDIX CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
B-CELL LYMPHOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
BASAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0013 events2 affected1,096 at risk
BLADDER CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
BLADDER NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
BLADDER TRANSITIONAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
BLADDER TRANSITIONAL CELL CARCINOMA RECURRENT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
BRAIN CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
BREAST CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
CHOLANGIOCARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CHOLESTEATOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CHRONIC LYMPHOCYTIC LEUKAEMIA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CHRONIC MYELOID LEUKAEMIA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
COLON ADENOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
COLON CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
DIFFUSE LARGE B-CELL LYMPHOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
GASTRIC CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
INVASIVE LOBULAR BREAST CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
LARGE INTESTINE BENIGN NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
LIPOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
LUNG ADENOCARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
LUNG CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
LUNG CARCINOMA CELL TYPE UNSPECIFIED RECURRENT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE III	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
LUNG NEOPLASM MALIGNANT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0016 events6 affected1,096 at risk
LYMPHOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
MALIGNANT MELANOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0012 events2 affected1,096 at risk
MALIGNANT PERITONEAL NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
METASTASES TO LIVER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
METASTASES TO LUNG	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
METASTATIC GASTRIC CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
METASTATIC MALIGNANT MELANOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
METASTATIC NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0003 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
MYELODYSPLASTIC SYNDROME	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
NEUROENDOCRINE CARCINOMA METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
NON-SMALL CELL LUNG CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
OESOPHAGEAL ADENOCARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
OESOPHAGEAL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events1 affected1,096 at risk
OVARIAN ADENOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
PANCREATIC CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
PLASMA CELL MYELOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
PROSTATE CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0006 events6 affected1,108 at risk EG0014 events4 affected1,096 at risk
PROSTATE CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
PROSTATE CANCER STAGE III	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
RECTAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
RENAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
SALIVARY GLAND NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
SQUAMOUS CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0006 events3 affected1,108 at risk EG0011 events1 affected1,096 at risk
SQUAMOUS CELL CARCINOMA OF SKIN	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
THROAT CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
THYROID ADENOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
TRANSITIONAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
ALTERED STATE OF CONSCIOUSNESS	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CAROTID ARTERIOSCLEROSIS	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CAROTID ARTERY OCCLUSION	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CAROTID ARTERY STENOSIS	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CARPAL TUNNEL SYNDROME	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
CEREBRAL HAEMORRHAGE	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
CEREBROVASCULAR ACCIDENT	Nervous system disorders	Systematic Assessment	EG00022 events22 affected1,108 at risk EG00139 events33 affected1,096 at risk
CERVICAL MYELOPATHY	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
DEMENTIA	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DEMENTIA ALZHEIMER'S TYPE	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DIZZINESS	Nervous system disorders	Systematic Assessment	EG0007 events7 affected1,108 at risk EG0018 events8 affected1,096 at risk
DYSARTHRIA	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ENCEPHALOPATHY	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
EPILEPSY	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events1 affected1,096 at risk
HAEMORRHAGE INTRACRANIAL	Nervous system disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0012 events2 affected1,096 at risk
HAEMORRHAGIC STROKE	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HYPERTONIA	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
METABOLIC ENCEPHALOPATHY	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
MYELOPATHY	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
NERVOUS SYSTEM DISORDER	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
PARKINSON'S DISEASE	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
PHRENIC NERVE PARALYSIS	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
POLYNEUROPATHY	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
POST-INJECTION DELIRIUM SEDATION SYNDROME	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
PRESYNCOPE	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
RADICULOPATHY	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
SCIATICA	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
SEIZURE	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
SPINAL CORD DISORDER	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
SPINAL CORD HAEMORRHAGE	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
SUBARACHNOID HAEMORRHAGE	Nervous system disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0012 events2 affected1,096 at risk
SYNCOPE	Nervous system disorders	Systematic Assessment	EG00017 events15 affected1,108 at risk EG00122 events19 affected1,096 at risk
TRANSIENT ISCHAEMIC ATTACK	Nervous system disorders	Systematic Assessment	EG00020 events20 affected1,108 at risk EG00121 events19 affected1,096 at risk
TRIGEMINAL NEURITIS	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
UNRESPONSIVE TO STIMULI	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
VIITH NERVE PARALYSIS	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DEVICE BATTERY ISSUE	Product Issues	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DEVICE DAMAGE	Product Issues	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
DEVICE DISLOCATION	Product Issues	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DEVICE INAPPROPRIATE SHOCK DELIVERY	Product Issues	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DEVICE ISSUE	Product Issues	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DEVICE OCCLUSION	Product Issues	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
THROMBOSIS IN DEVICE	Product Issues	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ANXIETY	Psychiatric disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
COMPLETED SUICIDE	Psychiatric disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DELIRIUM	Psychiatric disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
MAJOR DEPRESSION	Psychiatric disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
MENTAL STATUS CHANGES	Psychiatric disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
SUICIDE ATTEMPT	Psychiatric disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ACUTE KIDNEY INJURY	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0012 events2 affected1,096 at risk
CALCULUS BLADDER	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
CALCULUS URETERIC	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HAEMATURIA	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0015 events5 affected1,096 at risk
HYDRONEPHROSIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
NEPHROLITHIASIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0013 events3 affected1,096 at risk
NEPHROTIC SYNDROME	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
RENAL ARTERY STENOSIS	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
RENAL COLIC	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
RENAL FAILURE	Renal and urinary disorders	Systematic Assessment	EG00018 events16 affected1,108 at risk EG00110 events9 affected1,096 at risk
RENAL HAEMORRHAGE	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
RENAL IMPAIRMENT	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0013 events3 affected1,096 at risk
RENAL MASS	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
TUBULOINTERSTITIAL NEPHRITIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
URETEROLITHIASIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
URETHRAL CYST	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
URETHRAL STENOSIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0014 events2 affected1,096 at risk
URINARY INCONTINENCE	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
URINARY RETENTION	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
BENIGN PROSTATIC HYPERPLASIA	Reproductive system and breast disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0011 events1 affected1,096 at risk
FEMALE GENITAL TRACT FISTULA	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
OVARIAN MASS	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
PELVIC FLUID COLLECTION	Reproductive system and breast disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
POSTMENOPAUSAL HAEMORRHAGE	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
PROSTATOMEGALY	Reproductive system and breast disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
VAGINAL HAEMORRHAGE	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
ACUTE RESPIRATORY DISTRESS SYNDROME	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
ACUTE RESPIRATORY FAILURE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
ASTHMA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0008 events2 affected1,108 at risk EG0016 events4 affected1,096 at risk
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0015 events5 affected1,096 at risk
CHRONIC RESPIRATORY FAILURE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DYSPHONIA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
DYSPNOEA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0009 events9 affected1,108 at risk EG00112 events11 affected1,096 at risk
DYSPNOEA EXERTIONAL	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
EPISTAXIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
HAEMOPTYSIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
HAEMOTHORAX	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
INTERSTITIAL LUNG DISEASE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
PLEURAL EFFUSION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00012 events8 affected1,108 at risk EG0019 events9 affected1,096 at risk
PLEURITIC PAIN	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
PNEUMOTHORAX	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0003 events3 affected1,108 at risk EG0011 events1 affected1,096 at risk
PULMONARY CONGESTION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
PULMONARY EMBOLISM	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0004 events4 affected1,108 at risk EG0015 events5 affected1,096 at risk
PULMONARY FIBROSIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
PULMONARY HYPERTENSION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
PULMONARY MASS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
PULMONARY OEDEMA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0008 events8 affected1,108 at risk EG0013 events3 affected1,096 at risk
PULMONARY TOXICITY	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0012 events2 affected1,096 at risk
PULMONARY VEIN STENOSIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
RESPIRATORY DEPRESSION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0012 events2 affected1,096 at risk
RESPIRATORY DISTRESS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0012 events2 affected1,096 at risk
RESPIRATORY FAILURE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0004 events3 affected1,108 at risk EG0014 events4 affected1,096 at risk
SLEEP APNOEA SYNDROME	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0004 events4 affected1,108 at risk EG0016 events3 affected1,096 at risk
WHEEZING	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ANGIOEDEMA	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
DIABETIC FOOT	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0003 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
ERYTHEMA	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
CYTOREDUCTIVE SURGERY	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
HERNIA REPAIR	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
HIP ARTHROPLASTY	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
IMPLANTABLE DEFIBRILLATOR REMOVAL	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
IMPLANTABLE DEFIBRILLATOR REPLACEMENT	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
AORTIC ANEURYSM	Vascular disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
AORTIC ANEURYSM RUPTURE	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
AORTIC DILATATION	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
AORTIC OCCLUSION	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
AORTIC STENOSIS	Vascular disorders	Systematic Assessment	EG0004 events4 affected1,108 at risk EG0011 events1 affected1,096 at risk
ARTERIOSCLEROSIS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
ARTERIOVENOUS FISTULA	Vascular disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0010 events0 affected1,096 at risk
DEEP VEIN THROMBOSIS	Vascular disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
EMBOLISM	Vascular disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0014 events4 affected1,096 at risk
GRANULOMATOSIS WITH POLYANGIITIS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
HAEMATOMA	Vascular disorders	Systematic Assessment	EG00017 events17 affected1,108 at risk EG0013 events3 affected1,096 at risk
HAEMORRHAGE	Vascular disorders	Systematic Assessment	EG0009 events7 affected1,108 at risk EG0019 events9 affected1,096 at risk
HYPERTENSION	Vascular disorders	Systematic Assessment	EG0008 events7 affected1,108 at risk EG00110 events10 affected1,096 at risk
HYPERTENSIVE CRISIS	Vascular disorders	Systematic Assessment	EG00010 events9 affected1,108 at risk EG00114 events11 affected1,096 at risk
HYPOTENSION	Vascular disorders	Systematic Assessment	EG0008 events8 affected1,108 at risk EG0012 events2 affected1,096 at risk
INTERMITTENT CLAUDICATION	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ISCHAEMIA	Vascular disorders	Systematic Assessment	EG0006 events5 affected1,108 at risk EG00110 events10 affected1,096 at risk
LYMPHATIC FISTULA	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
ORTHOSTATIC HYPOTENSION	Vascular disorders	Systematic Assessment	EG0002 events2 affected1,108 at risk EG0011 events1 affected1,096 at risk
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
PERIPHERAL ARTERY ANEURYSM	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
PERIPHERAL ARTERY THROMBOSIS	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk
PERIPHERAL EMBOLISM	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
PERIPHERAL VENOUS DISEASE	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0011 events1 affected1,096 at risk
VASCULAR STENOSIS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,108 at risk EG0010 events0 affected1,096 at risk
VASCULITIS	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,108 at risk EG0011 events1 affected1,096 at risk

ID	Term
D006331	Heart Diseases
D002318	Cardiovascular Diseases
D010335	Pathologic Processes
D013568	Pathological Conditions, Signs and Symptoms

ID	Title	Description
BG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.
BG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.
BG002	Total	Total of all reporting groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Left Atrial Ablation	All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.	58	1,108	454	1,108	0	1,108
EG001	Rate or Rhythm Control Therapy	All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.	67	1,096	430	1,096	0	1,096